Introduction {#s1}
============

Despite major advances in global tuberculosis (TB) control and a significant reduction in cases, the global burden of TB is considerable, with an estimated 10.5 million new cases reported in 2015, and ∼1.4 million TB-related deaths \[[@C1]\]. The End TB strategy \[[@C2]\], developed by the World Health Organization (WHO) seeks to dramatically decrease TB incidence, mortality and catastrophic costs due to TB and aims for TB elimination (\<1 case per million) in low-incidence countries. Achieving these targets, and particularly the drive for TB elimination requires optimising all tools currently at our disposal and developing new ones \[[@C3]--[@C5]\].

Treatment of latent TB infection (LTBI) is highly effective in preventing TB reactivation \[[@C6], [@C7]\], and LTBI treatment has a recognised role in the End TB strategy \[[@C2]\]. While there is national \[[@C8]\] and international \[[@C9]\] guidance on target populations, screening modes and treatment regimens, there are still large gaps in the evidence, including better estimation of the LTBI progression risk in different population groups \[[@C9]\].

TB incidence in England is comparatively high (10.5 per 100 000), and ∼73% of notified cases occur among foreign-born individuals, most (85%) \>2 years after entry to the UK \[[@C10]\]. Recognising the need to tackle LTBI systematically, the collaborative TB strategy for England recommends, supports and funds programmatic LTBI testing and treatment in migrants from high-incidence countries \[[@C11]\].

Systematic testing for LTBI among migrants has been performed in the local authority area of Blackburn with Darwen since 1989. The initial scheme (1989--2001) used a single tuberculin skin test (TST) with follow-up for active cases and information/advice for TST-positive patients, but no LTBI treatment in line with former national guidance \[[@C12]\]. LTBI progression rates in this cohort were very high \[[@C13]\]. Subsequently (from 2009), an interferon-γ release assay (IGRA)-based programme was implemented and LTBI-positive patients were offered standard LTBI treatment. Matching this entire cohort to the UK enhanced TB surveillance (ETS) system enables follow-up for active TB case progression until the end of 2014.

The aim of this study is to review the evidence of this long-standing LTBI screening initiative in England to elicit lessons learned, better quantify progression and its risk factors and to shape and inform policy around LTBI screening nationally and internationally.

Methods {#s2}
=======

Study design and cohort {#s2a}
-----------------------

A retrospective cohort study was undertaken, based on data systematically collected on all persons undergoing the Blackburn TST-based LTBI screening programme between 1989 and 2001 and the IGRA-based LTBI screening and treatment programme between 2009 and 2013. Both screening programmes were aimed at recent migrants from high TB incidence areas, identified through new registration with primary care or through referral from the port of arrival after exclusion of active TB. Screening was limited to persons aged \<35 years.

The cohort was established through linking the screening databases with the UK ETS system. The screening databases contained basic demographic details, including age, sex, ethnicity, country of birth, screening dates and results, as well as details of LTBI treatment and completion. Bacille Calmette--Guerin (BCG) vaccination status was only available for the TST database. A wide range of details was available for notified TB cases, including demographic information, notification dates and details of the type of disease and treatment. Death information was derived from the national TB register (ETS), which is regularly validated through Office for National Statistics (ONS) death data.

Our primary outcome was active TB disease and the secondary outcome was incident TB. Definitions are outlined in [table 1](#TB1){ref-type="table"}.

###### 

Definitions

  ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Active TB disease**    Either having evidence of a positive culture of *Mycobacterium tuberculosis* complex or clinical and/or radiological evidence of TB with clinician\'s decision to treat with a full course of anti-TB treatment\
                           Denotified cases or those with notification dates before their LTBI testing were excluded from analysis

  **Incident TB cases**    Active cases notified \>60 days after the LTBI test date\
                           We would expect cases detected through screening (prevalent TB cases) to be notified within this period, but tested this assumption with a sensitivity analysis varying the cut-off between 30 and 90 days

  **Prevalent TB cases**   Active cases notified within 60 days of the screening date

  **LTBI**                 Either a positive TST or a positive IGRA (QuantiFERON-TB) test in the absence of active TB

                           A positive TST required either a positive skin reaction Heaf grade 2--4 (equivalent to 6 mm Mantoux reaction) in the absence of prior BCG vaccination or a Heaf grade 3--4 (equivalent to 15 mm Mantoux reaction) for individuals with BCG vaccination
  ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TB: tuberculosis; LTBI: latent TB infection; TST: tuberculin skin test; IGRA: interferon-γ release assay; BCG: bacille Calmette--Guerin.

Data linkage {#s2b}
------------

We linked the TST and QuantiFERON test (QFT) screening databases to the ETS system through deterministic matching *via* a common identifier (National Health Service (NHS) number), where available. In addition, and to overcome missing NHS numbers in both databases, we matched records through a validated probabilistic record linkage system based on agreement or partial agreement between demographic patient information. This methodology, initially developed by N[ewcombe]{.smallcaps} \[[@C14]\] has been adapted for infectious disease work \[[@C15]\] and validated \[[@C16]\].

Individuals entered the cohort at the date of their LTBI test and exited upon notification of death or becoming a TB case, their emigration from the UK or the study end date (December 31, 2014). The emigration date was imputed, using the rules outlined below. In addition, we explored the impact of the assumptions, including emigration rates, underlying the imputation using sensitivity analysis.

Multiple imputation and sensitivity analysis {#s2c}
--------------------------------------------

The duration of stay determining the exit date was imputed using length-of-stay information by visa type from the UK ONS between 2005 and 2013 \[[@C17]\]. Visa information was not routinely collected as part of the study, but assigned based on probability according to visa type distributions for that particular country. Those assigned family settlement/reunion visas were assumed to stay until the study end date, whereas work and study visas were randomly assigned a length of stay according to a uniform distribution, with lower and upper bounds according to the assigned duration category, and an upper bound of 10 years if assigned to the ≥4-year duration category. In addition, age-specific ONS mortality rates were applied. Death ascertainment for cases is completed through the ETS system; however, there is a very small chance of death among the rest of the cohort and a date of death was randomly assigned to each individual, which truncates follow-up time if the imputed date precedes the end of the study period or the imputed length of stay.

The imputation procedure assumes that the remaining duration of stay at the start of the study is the length of the entire UK stay, given that no information was available on how long into the duration of stay participants were at the start of the study. This could result in an overestimate of the remaining duration of UK stay to some extent, given that the distributions used are unbiased.

Completion rates for country of birth were 99.2% (1330 out of 1341) and 54.1% (259 out of 479) for the QFT and TST cohorts, respectively. Where country of birth was missing (13.5% of records), this was assigned based on the Onomap software (PublicProfiler, Newcastle, UK) using forename and surname. A small number of cases could not be assigned using Onomap and were randomly assigned a country of birth based on the overall distribution of observed countries.

The imputation process was repeated 10 times to produce a multiple imputation dataset, which was analysed according to R[ubin\']{.smallcaps}s \[[@C18]\] rules; this procedure conducts a separate analysis of every dataset and takes an average of the results, with confidence intervals accounting for both within- and between-imputation uncertainty.

Although the multiple imputation dataset reflects the statistical uncertainty of the estimated cohort time based on our data, this rests on the assumption that these data provide an accurate representation of the length-of-stay distribution for the participants in this study. As this cannot be verified, we undertook sensitivity analyses using the 25th and 75th percentiles of imputed cohort time for each individual and repeated the analysis based on the sets of lower and higher values. In addition, we varied the exclusion period for incident cases between 30 and 90 days.

Analysis {#s2d}
--------

The screening data were cleaned and de-duplicated, and where appropriate recoded to analysis-specific exposures and outcomes. Descriptive analysis was performed with cross-tabulation and calculation of incidence rates, means and medians, as appropriate. Significance testing was performed with Chi-squared and Fisher\'s exact tests, as appropriate. Single and multivariable analysis was performed using Poisson regression (suitable for rare outcomes) to estimate incidence rates and incidence rate ratios (IRR).

We performed all descriptive and multivariate analyses with Stata 13 (StataCorp, College Station, TX, USA). Simple figures were drawn using Excel 2011 (Microsoft, Redmond, WA, USA).

Results {#s3}
=======

Descriptive analysis {#s3a}
--------------------

Screening using TST occurred between January 1989 and November 2001 and that using QFT between January 2009 and December 2013. The latest follow-up date was December 31, 2014. The total cohort time was 6372 person-years, split into 3064 person-years for the QFT cohort and 3308 person-years for the TST cohort. The median follow-up for patients in the QFT cohort was 2.24 years (interquartile range (IQR) 1.8--2.7 years) and for patients in the TST cohort was 6.3 years (IQR 5.9--6.9 years) ([table 2](#TB2){ref-type="table"}).

###### 

Baseline characteristics of the cohorts

                                      **QFT^−^**          **QFT^+^**          **TST^+^**       **All subjects**
  ------------------------------- ------------------- ------------------- ------------------- -------------------
  **Total**                               975                 366                 479                1820
  **Total follow-up years**             2259.1               804.8              3308.3              6372.2
  **Average follow-up years**       2.3 (1.8--2.7)      2.2 (1.7--2.7)      6.3 (5.9--6.9)      2.5 (1.9--3.5)
  **Age at screening years**       25.2 (22.1--28.7)   26.4 (22.8--29.5)   24.3 (21.6--27.9)   25.1 (22.1--28.6)
  **Female**                          474 (48.6)          146 (39.8)          188 (39.2)          808 (44.4)
  **World area of birth**                                                                     
   South Asia                         777 (79.7)          303 (82.7)          442 (92.2)          1522 (83.6)
   North Africa and Middle East        39 (4.0)             7 (1.9)            19 (3.9)            65 (3.6)
   Sub-Saharan Africa                  58 (5.9)            31 (8.4)             9 (1.8)            98 (5.4)
   Eastern Europe and Russia           53 (5.4)            10 (2.7)              0 (0)             63 (3.5)
   Western Europe                        0 (0)               0 (0)              4 (0.8)             4 (0.2)
   East and south-east Asia            47 (4.8)            12 (3.2)             4 (0.8)            63 (3.5)
   South America                        1 (0.1)              1 (0)               0 (0)              2 (0.1)
   Unknown                               0 (0)              2 (0.5)              1 (0)              3 (0.2)

Data are presented as n, median (interquartile range) or n (%). QFT: QuantiFERON; TST: tuberculin skin test.

A total of 1820 persons were recorded as screened; 1341 with IGRA and 479 with TST. 366 (27.3%) IGRAs and all TSTs were positive. ∼66.4% (243 out of 366) of IGRA-positive patients initiated LTBI treatment. The most common reason for noninitiation of treatment was nonattendance or loss to follow-up (n=106, 86.2%), eight (6.5%) were prevalent active cases and four (3.3%) moved out of the area. Reasons for the remainder were unknown ([figure 1](#F1){ref-type="fig"}). The median (IQR) time from test to treatment start was 49 (28--101) days. 10 (4.1%) patients did not complete chemoprophylaxis (\<90% of treatment days); none of these developed TB. As per protocol, no treatment occurred in the TST cohort.

The majority of tests in both cohorts were performed in a young adult population and the median age at screening was 25.1 years (IQR 22.1--28.6 years, range 9.6--44 years) and in both testing cohorts there were more males (n=1012, 55.6%) than females (n= 808, 44.4%).

Most of the tests in both cohorts were performed on persons from the Indian subcontinent, and among those the largest proportions were from Pakistan (55.1%) and India (25.3%). There were smaller numbers of persons from sub-Saharan Africa, North Africa/Middle East and East/South-east Asia ([table 2](#TB2){ref-type="table"}). BCG vaccination and having a TB case in the family was only systematically recorded in the TST cohort. 16 individuals were recorded to have had a case of TB in the family, six of whom developed TB, and 125 (26.1%) persons had a BCG scar.

![Flowchart of tuberculosis (TB) cases in the different cohorts. IGRA: interferon-γ release assay; TST: tuberculin skin test; LTBI: latent TB infection.](ERJ-02505-2016.01){#F1}

### Active cases {#s3a1}

Matching to the ETS system identified 83 TB patients (this includes 23 cases not reported previously \[[@C13]\]); most of these (n=12) were identified after the end of the previous study or lost to follow-up (n=8). 16 cases were identified locally, but not reported nationally, as testing dates (1989--1998) predated ETS reporting.

We removed two cases from the analysis, because they occurred prior to LTBI testing; the total number of active TB cases in this cohort was therefore 97. 21 of these were from the QFT cohort and 76 were from the TST cohort. Characteristics of cases are presented in [table 3](#TB3){ref-type="table"}. In the QFT cohort 17 active cases were LTBI-positive and four were LTBI-negative. All patients in the TST cohort were test-positive and LTBI treatment naïve, and the overall proportion of active cases among the TST cohort was 15.9% (76 out of 479).

###### 

Baseline characteristics of tuberculosis (TB) cases

                                            **QFT cohort**      **TST cohort**          **All**
  --------------------------------------- ------------------- ------------------- -------------------
  **Total cases**                                 21                  76                  97
  **Incident cases**                           13 (61.9)          76 (100.0)           89 (91.8)
  **Site of disease**                                                             
   Pulmonary TB (+/− extrapulmonary TB)        10 (47.6)           21 (35.0)           31 (38.3)
   Extrapulmonary TB only                      11 (52.4)           39 (65.0)           50 (31.0)
  **Any first-line resistance**                 0 (0.0)             1 (1.3)             1 (1.0)
  **Time between... years**                                                       
   UK entry to case reporting               1.3 (0.9--3.0)      6.7 (2.7--11.6)     4.4 (1.9--7.9)
   LTBI test to case reporting              0.2 (0.1--2.0)       6.8 (3.6--11)      4.7 (1.8--8.3)
  **Age at reporting years**               28.1 (24.0--31.3)   30.0 (25.3--35.6)   29.1 (25.1--32.5)
  **BCG**                                                                         
   Yes                                         4 (26.7)            17 (24.3)           21 (24.7)
   No                                          11 (73.3)           53 (75.7)           64 (75.3)
  **Sex**                                                                         
   Female                                      9 (42.9)            40 (52.6)           49 (50.5)
   Male                                        12 (57.1)           36 (47.4)           48 (49.5)
  **World area of birth**                                                         
   South Asia                                  19 (90.5)           74 (97.4)           93 (95.9)
   Sub-Saharan Africa                           2 (9.5)             1 (1.3)             3 (3.1)
   East and south-east Asia                     0 (0.0)             1 (1.3)             1 (1.0)
  **Ethnicity**                                                                   
   Black African                                2 (9.5)             0 (0.0)             2 (2.5)
   Indian                                      9 (42.9)            21 (35.6)           30 (37.5)
   Pakistani                                   9 (42.9)            36 (61.0)           45 (56.3)
   Bangladeshi                                  0 (0.0)             2 (3.4)             2 (2.5)
   Mixed/other                                  1 (4.8)             0 (0.0)             1 (1.3)

Data are presented as n, n (%) or median (interquartile range). QFT: QuantiFERON; TST: tuberculin skin test; LTBI: latent TB infection; BCG: bacille Calmette--Guerin.

48 (50.1%) of TB cases were female, and all of them young adults at the time of case reporting (median 23.6 years, range 16--34.5 years). Most cases were of South Asian ethnicity (Indian n=28, Pakistani n=45 and Bangladeshi n=2) ([table 3](#TB3){ref-type="table"}). Patients had entered the UK between 1989 and 2012, and approximately half (51%) had entered the UK prior to 2000. The median (IQR) time between UK entry and the date of testing was 106 days (0--293 days).

The distribution of pulmonary and extrapulmonary TB was relatively even in the QFT cohort (extrapulmonary cases n=9, 47.4%,), whereas in the TST cohort most cases had extrapulmonary TB (n=39, 65%).

### Incident active cases {#s3a2}

Since we analysed the effects of screening and treatment for LTBI, another important outcome of our study is incident cases, because these might have occurred as a result of LTBI reactivation. 13 (61.9%) patients in the QFT cohort and all patients in the TST cohort were incident cases. 13 (10.6%) out of the 123 untreated LTBI-positive patients in the QFT cohort developed TB, compared with four (1.7%) of the 243 treated LTBI-positive patients in the QFT cohort (p=0.001). Excluding eight of the 21 cases in the QFT cohort as prevalent, 13 cases remained, of which four cases were LTBI-negative and nine cases were LTBI-positive. Of these positive cases, six (5.2%) incident cases occurred among the 116 untreated patients compared with three (1.2%) among the 242 treated patients in the QFT cohort (p= 0.026).

For non-UK-born TB patients, time since entry to the UK is often used as proxy for time since TB infection. The median (IQR) time between UK entry and reporting date was 1.3 (0.9--3.0) years for the QFT cohort and 6.7 (2.7--11.6) years for the TST cohort ([figure 2a and b](#F2){ref-type="fig"}). Among untreated LTBI-positive patients, early incidence is higher in the QFT group (incidence rate 236 *versus* 139 per 100 000 person-years after 2 years); most cases (n=54, 71%) occurred \>5 years after entry to the UK in the TST cohort.

![Time between UK entry and case notification for a) the tuberculin skin test cohort and b) the QuantiFERON cohort.](ERJ-02505-2016.02){#F2}

Multivariate analysis {#s3b}
---------------------

Incidence rates and IRRs for the QFT cohort were calculated using Poisson regression analysis. The crude TB rate in the QFT cohort was 0.6 per 100 person years, increasing to 4.1 per 100 person-years for those who were test-positive and treatment-naïve. Testing QFT-positive (IRR 22.6, 95% CI 6.9--74.6), no treatment for LTBI (IRR 0.17, 95% CI 0.05--0.6) and being male (IRR 0.88, 95% CI 0.35--2.2) were associated with becoming a TB case ([table 4a](#TB4){ref-type="table"}). After adjusting for confounders, treatment for LTBI therefore reduced the risk of reactivation by an estimated 83%.

###### 

Incidence rates (IR) and Poisson analysis of the QuantiFERON test (QFT) cohort, with all tuberculosis (TB) cases and incident cases as outcome

                                **All cases**   **Incident cases**                                                                                                                                                          
  ---------------------------- --------------- -------------------- ------------------------- --------------------------- --------- -------- ----- -------- ------------------------- --------------------------- --------- --------
  **QFT-negative**                    4               2259.1         0.0018 (0.0005--0.0045)             Ref.                                  4    2259.1   0.0018 (0.0005--0.0045)             Ref.                       
  **QFT-positive**                   15               804.8          0.0186 (0.0104--0.0307)   22.6435 (6.8743--74.5860)   \<0.001             9    804.8    0.0112 (0.0051--0.0212)   12.7057 (3.4510--46.7796)   \<0.001   0.0012
  **No LTBI treatment^\#^**          11               265.6          0.0414 (0.0207--0.0741)             Ref.                                  6    265.6    0.0226 (0.0083--0.0492)             Ref.                       
  **LTBI treatment**^\#^****          4               539.3          0.0074 (0.0020--0.0190)    0.1711 (0.0486--0.6020)    0.0060    0.0014    3    539.3    0.0056 (0.0011--0.0163)    0.2249 (0.0508--0.9967)     0.049    0.039
  **Female**                          8               1371.7         0.0058 (0.0025--0.0115)             Ref.                                  5    1371.7   0.0036 (0.0012--0.0085)             Ref.                       
  **Male**                           11               1690.1         0.0065 (0.0032--0.0116)    0.8780 (0.3546--2.1739)    0.7790    0.0200    8    1690.1   0.0047 (0.0020--0.0093)    1.1095 (0.3621--3.3999)     0.856     0.8
  **Age**                                                                                      --1.0239 (0.9390--1.1165)   0.5930    0.1800                                             1.0076 (0.9062--1.1205)     0.888     0.9
  **Area of birth**                                                                                                                                                                                                         
   Indian subcontinent               17               2432.3         0.0070 (0.0041--0.0112)             Ref.                                  12   2432.3   0.0049 (0.0025--0.0086)             Ref.                       
   Sub-Saharan Africa                 2               248.8          0.0080 (0.0010--0.0290)    0.7514 (0.1491--3.7856)    0.7290              1    248.8    0.0040 (0.0001--0.0224)    0.5293 (0.0657--4.2641)     0.55    
   Rest of world                      0               382.9          0.0000 (0.0000--0.0096)    0.0000 (0.0000--0.0000)    \<0.001   0.1140    0    382.9    0.0000 (0.0000--0.0096)    0.0000 (0.0000--0.0000)    \<0.001    0.2

Data are presented as n, unless otherwise stated. IRR: incidence rate ratio; LR: likelihood ratio; LTBI: latent TB infection. ^\#^: of persons with positive LTBI test.

In our analysis of incident cases the crude incidence rate was 0.4 per 100 person-years, increasing to 2.3 per 100 person-years among the test-positive, treatment-naïve cohort. Multivariate analysis demonstrated significance of the same exposure factors as in the overall TB case analysis, albeit with changed effect sizes (positive test IRR 12.7, 95% CI 3.5--46.8 and chemoprophylaxis IRR 0.2, 95% CI 0.05--0.99) ([table 4](#TB4){ref-type="table"}).

Lastly we compared how well TST and QFT predicted TB cases among the combined test-positive, treatment-naïve cohort in multivariate analysis. QFT was a significantly better predictor of an individual becoming a TB case than TST in our cohort (IRR 2.3, 95% CI 1.9--4.3) ([table 5](#TB5){ref-type="table"}).

###### 

Incidence rates (IR) and Poisson analysis of predictive value of tuberculin skin test (TST) *versus* QuantiFERON test (QFT) in test-positive, treatment-naïve cohort; outcome is tuberculosis (TB) case

                          **TB events**   **Person-years**     **IR (95% CI)**        **IRR (95% CI)**     **p-value**   **LR test**
  ---------------------- --------------- ------------------ ---------------------- ---------------------- ------------- -------------
      **TST tested**           76              3308.3        0.023 (0.018--0.029)           Ref.                        
      **QFT tested**           11              265.6         0.041 (0.021--0.074)   2.270 (1.188--4.338)      0.013     
        **Female**             48              2693.2        0.018 (0.013--0.024)           Ref.                        
         **Male**              47              3676.9        0.013 (0.009--0.017)   0.674 (0.439--1.036)      0.072         0.026
   **Age (continuous)**                                                             0.964 (0.916--1.014)      0.152         0.125
    **Area of birth**                                                                                                   
    Indian subcontinent        91              5541.5        0.016 (0.013--0.020)           Ref.                        
    Sub-Saharan Africa          3              315.1         0.010 (0.002--0.028)   0.301 (0.040--2.232)      0.240     
       Rest of world            1              515.6         0.002 (0.000--0.011)   0.221 (0.031--1.594)      0.134         0.060

Data are presented as n, unless otherwise stated. IRR: incidence rate ratio; LR: likelihood ratio.

We performed a number of sensitivity analyses on our data, varying assumptions around cohort time and the definition of incident cases. While sensitivity analysis led to a change in incidence rates and effect estimates, they did not alter the main findings or the direction of effect.

Discussion {#s4}
==========

This article reports results from one of the longest running LTBI initiatives in England and perhaps globally. Cumulative reactivation rates were high in both cohorts, and particularly of note is the late reactivation rate in the TST cohort. Follow-up time in the QFT cohort was shorter, and during the observation time, QFT positivity appears to be better correlated with becoming a TB case than TST positivity. We confirmed the protective effect of LTBI treatment. Our study did not explore important secondary effects of such a screening programme, such as awareness raising or facilitating access to care, but these should be mentioned as other important effects of such a programme to support TB control.

We present an update on previously published results in the TST cohort, confirming an even greater reactivation rate than previously thought \[[@C13]\]. In keeping with previous research, we confirmed the better predictive value of QFT compared with TST in our cohort \[[@C19]\]; this is in contrast to current recommendations from the National Institute for Health and Care Excellence \[[@C8]\]. The comparative performance of these tests is particularly important when deciding on the best test strategy in the context of programmatic LTBI screening.

LTBI reactivation rates have been the subject of intense debate and estimates of progression vary widely. For example, R[angaka]{.smallcaps} *et al.* \[[@C20]\] estimated progression rates of between four and 48 cases per 1000 person-years in IGRA-positive individuals with a median follow-up time of 4 years. Another meta-analysis estimated progression rates to be 2.7% and 1.5% for IGRA and TST, respectively, rising to 6.8% and 2.4%, respectively if limiting to high-risk groups \[[@C19]\]. The same authors performed another systematic review with much higher reactivation estimates (8--15%) for IGRA-positive individuals, mostly in contact-tracing settings \[[@C21]\]. Conversely, a pan-European study estimated a reactivation rate of nine and 12 per 1000 person-years for QFT and T-Spot IGRA tests, respectively \[[@C22]\].

Some of this variation can be explained by individual or environmental risk factors, such as proximity of recent contact with a pulmonary case or immunosuppression. There is consensus on the need to define screening target groups well \[[@C9]\], and more detailed description of progression risk factors has been performed by K[ruijshaar]{.smallcaps} *et al*. \[[@C23]\], although it may be difficult to implement highly specific screening target groups for practical or societal reasons. Within these limits, the art of defining the most appropriate target group must carefully weigh reactivation risk, costs and benefits \[[@C24]\], as has been done in the national migrant LTBI testing and treatment programme in England.

Some of our findings are expected and have previously been described in the literature, such as the superiority of IGRA to predict LTBI reactivation \[[@C19]--[@C21]\], although both tests are recommended by the WHO \[[@C9]\], or the protective effect of chemotherapy to prevent TB cases \[[@C6], [@C7]\]. However, the high late TB rate in the TST cohort was unexpected, and instead of an initial peak, case numbers remained stable and high over a number of years. While the possibility of re-infection (*e.g.* through travel to high-incidence countries \[[@C25]\]) cannot be dismissed, both data and local knowledge appears to point to a relatively stable population and therefore potentially genuine observation of late reactivations. While acknowledging the limitations of TST (*e.g.* using Heaf test) and potential differences comparing the cohorts, these are interesting findings. Therefore, further work is needed to confirm these findings and elicit potential causes.

Our study has a number of strengths and limitations. We report observational data from a well-recorded, sizable cohort with long follow-up times, although observational data have well-known limitations. The length of the follow-up time is relevant, as due to the scarcity of observed reactivation data most knowledge is based on mathematical modelling only. In addition, the study benefits from its data-linkage to ETS with near complete case ascertainment in the UK. The probabilistic matching used has been validated before, and all detected cases have been scrutinised, so that the probability of over-ascertainment is very low, although there is a small probability that cases have been missed and under-ascertained.

However, a key limitation is that for most individuals, the date of exit out of the UK was unknown. We minimised this limitation through using multiple imputation based on known personal characteristics, and by using sensitivity analysis to model an upper and lower estimate of UK stay. Apart from the uncertainty of length of stay, the absence of observed exit data could have led to an under-ascertainment of cases occurring outside of the UK. While we are confident that we minimised the impact of these missing data, the most likely effect of the combined limitations noted above would be an underestimation of TB reactivation rates. Alternatively, if we underestimated length of stay for temporary visa types, this may lead to over-ascertainment of late cases and could be an alternative explanation for the rate of TB not decreasing as expected. Another limitation is the absence of information on comorbidities, which were thus not adjusted for in our models. Given that this was a young community cohort, and given that none of the TB cases had recorded immunosuppression, it is unlikely that this would have changed results. Lastly, it is also worth noting that the reading threshold influences positivity and effect size for the TST cohort. National (UK) recommendations were followed to determine positivity, but different reading thresholds may lead to different reactivation rate estimates.

In conclusion, our study demonstrates the feasibility and effectiveness of LTBI screening and treatment based on long-term outcomes in this cohort. It shows high TB reactivation rates and reaffirms the better predictive value of QFT based screening compared with TST. Based on this long-term initiative there are important lessons about effective prevention of TB reactivation to be considered for the national LTBI screening programme in England and elsewhere, particularly in the context of utilising LTBI screening and treatment in the context of TB elimination targets in low-incidence countries \[[@C3], [@C4]\].
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